JDD August 2023 Issue Highlights | Special Focus: Psoriasis
psoriasisWith a special focus on the topic of psoriasis, check out highlights from the August issue of the Journal of Drugs in Dermatology (JDD) straight from the JDD Editor’s desk: Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis delves into the expert guidance provided by the Psoriasis Expert Group (PEG), encompassing nine crucial statements that offer com …
psoriasis
My Approach to Recognizing, Diagnosing and Treating Psoriasis in Diverse Skin Tones
PSORIASISNext Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Amy McMichael, professor and chair of the department of dermatology at Wake Forest University School of Medicine, about her approach to recognizing, diagnosing and treating psoriasis in diverse skin tones. Watch as Dr. McMichael shares why psoriasis workups in patients with skin of color should be different. Don’t pro …
PSORIASIS
Facial Erythema – Friday Pop Quiz – 7/28/2023
A 60-year-old man presents with a tendency to flush combined with a background of persistent facial erythema. On exam, you notice a background of telangiectasias. He has maximized treatment with topical and oral medications and is considering laser treatment for his prominent blood vessels. Which is the laser of choice for this patient’s condition? A. Pulsed dye laser B. KTP laser C …
Patient Buzz: Melasma Moustache | The Expert Weighs In
melasmaGood Housekeeping recently posted an article on how to treat a melasma moustache. What should dermatology clinicians know about treating melasma on the upper lip? What are some up and coming melasma treatments that dermatology clinicians should be aware of? For expert advice, I reached out to Jennifer Rullan, MD, FAAD, a dermatologist in Chula Vista, Ca. How common is melasma on the upper l …
melasma
Baricitinib Therapeutic Cheat Sheet
BaricitinibBaricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l …
Baricitinib